Seminars in Radiation Oncology
Volume 20, Issue 3 , Pages 201-207 , July 2010

Radiation Pulmonary Toxicity: From Mechanisms to Management

  • Paul R. Graves, PhD

      Affiliations

    • Department of Radiation Oncology, Virginia Commonwealth University, Richmond, VA
    • Corresponding Author InformationAddress reprint requests to Paul R. Graves, PhD, Department of Radiation Oncology, Virginia Commonwealth University School of Medicine, 401 College Street, PO. Box 980058, Richmond, VA 23298-0058
    • ,
  • Farzan Siddiqui, MD, PhD

      Affiliations

    • Department of Radiation Oncology, Henry Ford Health System, Detroit, MI
    • ,
  • Mitchell S. Anscher, MD

      Affiliations

    • Department of Radiation Oncology, Virginia Commonwealth University, Richmond, VA
    • ,
  • Benjamin Movsas, MD

      Affiliations

    • Department of Radiation Oncology, Henry Ford Health System, Detroit, MI

References 

  1. Zhao W, Robbins ME. Inflammation and chronic oxidative stress in radiation-induced late normal tissue injury: Therapeutic implications. Curr Med Chem. 2009;16:130–143
  2. Trott KR, Herrmann T, Kasper M. Target cells in radiation pneumopathy. Int J Radiat Oncol Biol Phys. 2004;58:463–469
  3. Fleckenstein K, Zgonjanin L, Chen L. Temporal onset of hypoxia and oxidative stress after pulmonary irradiation. Int J Radiat Oncol Biol Phys. 2007;68:196–204
  4. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199–210
  5. Rube CE, Wilfert F, Palm J. Irradiation induces a biphasic expression of pro-inflammatory cytokines in the lung. Strahlenther Onkol. 2004;180:442–448
  6. Vujaskovic Z, Anscher MS, Feng QF. Radiation-induced hypoxia may peRILIetuate late normal tissue injury. Int J Radiat Oncol Biol Phys. 2001;50:851–855
  7. McDonald S, Rubin P, Phillips TL. Injury to the lung from cancer therapy: Clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys. 1995;31:1187–1203
  8. Kocak Z, Evans ES, Zhou SM. Challenges in defining radiation pneumonitis in patients with lung cancer. Int J Radiat Oncol Biol Phys. 2005;62:635–638
  9. Libshitz HI, Southard ME. Complications of radiation therapy: The thorax. Semin Roentgenol. 1974;9:41–49
  10. Ross WM. The radiotherapeutic and radiological aspects of radiation fibrosis of the lungs. Thorax. 1956;11:241–248
  11. Pagani JJ, Libshitz HI. Manifestations of radiation-induced change in chest tissue. J Comput Assist Tomogr. 1982;6:243–248
  12. De Ruysscher D, Houben A, Aerts HJ. Increased (18)F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent radiation-induced lung toxicity (RILT): A prospective pilot study. Radiother Oncol. 2009;91:415–420
  13. Tsougos I, Nilsson P, Theodorou K. NTCP modelling and pulmonary function tests evaluation for the prediction of radiation induced pneumonitis in non-small-cell lung cancer radiotherapy. Phys Med Biol. 2007;52:1055–1073
  14. Dehing-Oberije C, De Ruysscher D, van Baardwijk A. The importance of patient characteristics for the prediction of radiation-induced lung toxicity. Radiother Oncol. 2009;91:421–426
  15. De Jaeger K, Seppenwoolde Y, Boersma LJ. Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003;55:1331–1340
  16. Oetzel D, Schraube P, Hensley F. Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys. 1995;33:455–460
  17. Kwa SL, Lebesque JV, Theuws JC. Radiation pneumonitis as a function of mean lung dose: An analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 1998;42:1–9
  18. Graham MV, Purdy JA, Emami B. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;45:323–329
  19. Madani I, De Ruyck K, Goeminne H. Predicting risk of radiation-induced lung injury. J Thorac Oncol. 2007;2:864–874
  20. Hernando ML, Marks LB, Bentel GC. Radiation-induced pulmonary toxicity: A dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:650–659
  21. Armstrong JG, Zelefsky MJ, Leibel SA. Strategy for dose escalation using 3-dimensional conformal radiation therapy for lung cancer. Ann Oncol. 1995;6:693–697
  22. Bradley JD, Hope A, El Naqa I. A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. Int J Radiat Oncol Biol Phys. 2007;69:985–992
  23. Liao ZX, Komaki RR, Thames HD. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010;76:775–781
  24. Kyas I, Hof H, Debus J. Prediction of radiation-induced changes in the lung after stereotactic body radiation therapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;67:768–774
  25. Anscher MS, Peters WP, Reisenbichler H. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med. 1993;328:1592–1598
  26. Fu XL, Huang H, Bentel G. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. Int J Radiat Oncol Biol Phys. 2001;50:899–908
  27. Anscher MS, Marks LB, Shafman TD. Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:988–995
  28. Novakova-Jiresova A, Van Gameren MM, Rili C. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. Radiother Oncol. 2004;71:183–189
  29. Zhao L, Wang L, Ji W. Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer: A combined analysis from Beijing and Michigan. Int J Radiat Oncol Biol Phys. 2009;74:1385–1390
  30. Chen Y, Rubin P, Williams J. Circulating IL-6 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2001;49:641–648
  31. Ariliin D, Perol D, Blay JY. Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. J Clin Oncol. 2005;23:8748–8756
  32. Goto K, Kodama T, Sekine I. Serum levels of KL-6 are useful biomarkers for severe radiation pneumonitis. Lung Cancer. 2001;34:141–148
  33. Catane R, Schwade JG, Turrisi AT. Pulmonary toxicity after radiation and bleomycin: A review. Int J Radiat Oncol Biol Phys. 1979;5:1513–1518
  34. Movsas B, Raffin TA, Epstein AH. Pulmonary radiation injury. Chest. 1997;111:1061–1076
  35. Schaake-Koning C, van den Bogaert W, Dalesio O. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326:524–530
  36. Lee JS, Scott C, Komaki R. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group protocol 91-06. J Clin Oncol. 1996;14:1055–1064
  37. Taghian AG, Assaad SI, Niemierko A. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst. 2001;93:1806–1811
  38. Robnett TJ, Machtay M, Vines EF. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys. 2000;48:89–94
  39. Movsas B, Swann S, Curran WJ. Sociodemographic factors are significant predictors of toxicity in RTOG Non-operative NSCLC trials. Int J Radiat Oncol Biol Phys. 2006;66:S62
  40. Monson JM, Stark P, Reilly JJ. Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. Cancer. 1998;82:842–850
  41. Antonadou D, Coliarakis N, Synodinou M. Randomized phase III trial of radiation treatment +/− amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:915–922
  42. Antonadou D, Throuvalas N, Petridis A. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003;57:402–408
  43. Movsas B, Scott C, Langer C. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group trial 98-01. J Clin Oncol. 2005;23:2145–2154
  44. Chopra M, Scott N, McMurray J. Captopril: A free radical scavenger. Br J Clin Pharmacol. 1989;27:396–399
  45. Ozturk B, Egehan I, Atavci S. Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: A double-blind randomized trial. Int J Radiat Oncol Biol Phys. 2004;58:213–219
  46. Misirlioglu CH, Demirkasimoglu T, Kucukplakci B. Pentoxifylline and alpha-tocopherol in prevention of radiation-induced lung toxicity in patients with lung cancer. Med Oncol. 2007;24:308–311
  47. Gross NJ. Pulmonary effects of radiation therapy. Ann Intern Med. 1977;86:81–92
  48. Castellino RA, Glatstein E, Turbow MM. Latent radiation injury of lungs or heart activated by steroid withdrawal. Ann Intern Med. 1974;80:593–599
  49. Delanian S, Lefaix JL. Current management for late normal tissue injury: Radiation-induced fibrosis and necrosis. Semin Radiat Oncol. 2007;17:99–107
  50. Robb WB, Condron C, Moriarty M. Taurine attenuates radiation-induced lung fibrosis in C57/Bl6 fibrosis prone mice. Ir J Med Sci. 2009;179:99–105
  51. Para AE, Bezjak A, Yeung IW. Effects of genistein following fractionated lung irradiation in mice. Radiother Oncol. 2009;92:500–510
  52. Lee JC, Krochak R, Blouin A. Dietary flaxseed prevents radiation-induced oxidative lung damage, inflammation and fibrosis in a mouse model of thoracic radiation injury. Cancer Biol Ther. 2009;8:47–53
  53. Liu Y, Yu H, Zhang C. Protective effects of berberine on radiation-induced lung injury via intercellular adhesion molecular-1 and transforming growth factor-beta-1 in patients with lung cancer. Eur J Cancer. 2008;44:2425–2432
  54. Colon J, Herrera L, Smith J. Protection from radiation-induced pneumonitis using cerium oxide nanoparticles. Nanomedicine. 2009;5:225–231
  55. Epperly MW, Bray JA, Krager S. Intratracheal injection of adenovirus containing the human MnSOD transgene protects athymic nude mice from irradiation-induced organizing alveolitis. Int J Radiat Oncol Biol Phys. 1999;43:169–181
  56. Greenberger JS, Epperly MW, Gretton J. Radioprotective gene therapy. Curr Gene Ther. 2003;3:183–195
  57. Gauter-Fleckenstein B, Fleckenstein K, Owzar K. Comparison of two Mn poRILIhyrin-based mimics of superoxide dismutase in pulmonary radioprotection. Free Radic Biol Med. 2008;44:982–989
  58. Giaid A, Lehnert SM, Chehayeb B. Inducible nitric oxide synthase and nitrotyrosine in mice with radiation-induced lung damage. Am J Clin Oncol. 2003;26:e67–e72
  59. Nozaki Y, Hasegawa Y, Takeuchi A. Nitric oxide as an inflammatory mediator of radiation pneumonitis in rats. Am J Physiol. 1997;272:L651–L658
  60. Kulkarni AB, Huh CG, Becker D. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A. 1993;90:770–774
  61. Anscher MS, Murase T, Prescott DM. Changes in plasma TGF beta levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis. Int J Radiat Oncol Biol Phys. 1994;30:671–676
  62. Anscher MS, Thrasher B, Zgonjanin L. Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury. Int J Radiat Oncol Biol Phys. 2008;71:829–837
  63. Williams JP, Hernady E, Johnston CJ. Effect of administration of lovastatin on the development of late pulmonary effects after whole-lung irradiation in a murine model. Radiat Res. 2004;161:560–567
  64. Bao P, Gao W, Li S. Effect of pretreatment with high-dose ulinastatin in preventing radiation-induced pulmonary injury in rats. Eur J Pharmacol. 2009;603:114–119
  65. Werner-Felmayer G, Golderer G, Werner ER. Tetrahydrobiopterin biosynthesis, utilization and pharmacological effects. Curr Drug Metab. 2002;3:159–173
  66. Yang K, Palm J, Konig J. Matrix-metallo-proteinases and their tissue inhibitors in radiation-induced lung injury. Int J Radiat Biol. 2007;83:665–676
  67. Zhang M, Qian J, Xing X. Inhibition of the tumor necrosis factor-alpha pathway is radioprotective for the lung. Clin Cancer Res. 2008;14:1868–1876
  68. Wang C, Abe S, Matsuda K. Effects of gefitinib on radiation-induced lung injury in mice. J Nippon Med Sch. 2008;75:96–105
  69. Puthawala K, Hadjiangelis N, Jacoby SC. Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med. 2008;177:82–90
  70. Movsas B, Moughan J, Sarna L. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small cell lung cancer: An analysis of RTOG 9801. J Clin Oncol. 2009;27:5816–5822
  71. Sarna L, Swann S, Langer C. Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: An analysis of RTOG 9801. Int J Radiat Oncol Biol Phys. 2008;72:1378–1384

PII: S1053-4296(10)00018-4

doi: 10.1016/j.semradonc.2010.01.010

Seminars in Radiation Oncology
Volume 20, Issue 3 , Pages 201-207 , July 2010

Article Tools

* Image Usage & Resolution